nintedanib esylate
- RxCUI
- 1592736
- RxNorm name
- nintedanib esylate
- Term type
- PIN
- Status
- Active
- Updated
- 2026-06-04 07:08:38
RxNorm Status History#
- Status
- Active
- Source
- RXNORM
- Current
- YES
- Release start
- 122014
- Active start
- 122014
- Multiple ingredient
- NO
- Branded
- NO
Derived Ingredient Concepts#
| Ingredient | RxCUI |
|---|---|
| nintedanib | 1592737 |
Source Vocabulary Codes#
| Code type | Values | Count | Category |
|---|---|---|---|
| PRESCRIBABLE | Y | 1 | ATTRIBUTES |
| RXNAV_STR | nintedanib esylate | 1 | NAMES |
| RxNorm Name | nintedanib esylate | 1 | NAMES |
| TTY | PIN | 1 | ATTRIBUTES |
| SPL_SET_ID | 8 linked values | 8 | CODES |
| UNII_CODE | 42F62RTZ4G | 1 | CODES |
| RxCUI | 1592736 | 1 | CODES |
UNII Substances#
| UNII | Preferred term | Registry number | Source |
|---|---|---|---|
| 42F62RTZ4G | NINTEDANIB ESYLATE | 656247-18-6 | tbl_unii_list |
| 42F62RTZ4G | NINTEDANIB ESYLATE | 656247-18-6 | tbl_unii_list |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Nintedanib esylate | NINTEDANIB ESYLATE | Macleods Pharmaceuticals Limited | 9925b305-c1fb-43b6-a5fd-e03f14f28e6c | 2026-08-03 | Warnings, Adverse reactions | 42F62RTZ4G |
| Nintedanib | NINTEDANIB | Edenbridge Pharmaceuticals LLC. | 43dae004-eaf6-4411-8c3d-db7ab2c3b41e | 2026-07-29 | Warnings, Adverse reactions | 42F62RTZ4G |
| nintedanib | NINTEDANIB | AvKARE | 572722d7-338a-e4d2-e063-6394a90a257c | 2026-07-21 | Warnings, Adverse reactions | 42F62RTZ4G |
| nintedanib | NINTEDANIB | Glenmark Pharmaceuticals Inc., USA | b14164fb-0276-4ad1-a5ff-400ab9e292da | 2026-07-10 | Warnings, Adverse reactions | 42F62RTZ4G |
| nintedanib | NINTEDANIB | EPIC PHARMA LLC | 0e12f080-fcb4-465f-b988-4fa2c79f49aa | 2026-07-09 | Warnings, Adverse reactions | 42F62RTZ4G |
| Nintedanib | NINTEDANIB | Golden State Medical Supply, Inc. | 4ecf7f05-4a95-b98c-e063-6394a90ab896 | 2026-06-16 | Warnings, Adverse reactions | 42F62RTZ4G |
| Nintedanib Capsules, 100 mg and 150 mg | NINTEDANIB | EXELAN PHARMACEUTICALS INC. | 60d8104e-cb6c-4f4f-8159-95ed57346ffa | 2026-04-21 | Warnings, Adverse reactions | 42F62RTZ4G |
| Nintedanib | NINTEDANIB | Cipla USA Inc. | 4d017c42-a823-452d-bc6f-0491dd9823e3 | 2026-04-02 | Warnings, Adverse reactions | 42F62RTZ4G |
| Nintedanib | NINTEDANIB | Apotex Corp. | b72b26c3-7731-80c0-734b-a5f53a1d89ae | 2026-03-20 | Warnings, Adverse reactions | 42F62RTZ4G |
| nintedanib | NINTEDANIB | Sandoz Inc | 751c3473-35d6-47d6-b405-af16a989716c | 2026-01-20 | Warnings, Adverse reactions | 42F62RTZ4G |
| Nintedanib | NINTEDANIB | Dr. Reddy's Laboratories Inc. | 88f8600d-0974-51ca-6f8e-28c48a379e08 | 2025-11-20 | Warnings, Adverse reactions | 42F62RTZ4G |
| Ofev | NINTEDANIB | Boehringer Ingelheim Pharmaceuticals, Inc. | da1c9f37-779e-4682-816f-93d0faa4cfc9 | 2025-11-20 | Warnings, Adverse reactions | 42F62RTZ4G |
DailyMed RxNorm Mappings#
No records found.
Drug Classes#
| Source | Class ID | Class | Type | Relationship | Drug concept |
|---|---|---|---|---|---|
| ATC | L01EX | Other protein kinase inhibitors | ATC1-4 | nintedanib | |
| FDASPL | N0000175605 | Kinase Inhibitor | EPC | has_epc | nintedanib |
| FDASPL | N0000175076 | Protein Kinase Inhibitors | MOA | has_moa | nintedanib |
| MEDRT | D007211 | Indoles | CHEM | has_ingredient | nintedanib esylate |
| MEDRT | D007211 | Indoles | CHEM | has_ingredient | nintedanib |
| MEDRT | D054990 | Idiopathic Pulmonary Fibrosis | DISEASE | may_treat | nintedanib esylate |
| MEDRT | D054990 | Idiopathic Pulmonary Fibrosis | DISEASE | may_treat | nintedanib |
| MEDRT | N0000020000 | Receptor Tyrosine Kinase Inhibitors | MOA | has_moa | nintedanib esylate |
| MEDRT | N0000020000 | Receptor Tyrosine Kinase Inhibitors | MOA | has_moa | nintedanib |
| MEDRT | N0000175678 | Decreased Endothelial Proliferation | PE | has_pe | nintedanib esylate |
| MEDRT | N0000175678 | Decreased Endothelial Proliferation | PE | has_pe | nintedanib |
Properties#
| Category | Property | Value |
|---|---|---|
| ATTRIBUTES | GENERAL_CARDINALITY | SINGLE |
| CODES | SNOMEDCT | 863993005 |
| CODES | USP | m9925 |
| SOURCES | Source | Gold Standard Alchemy |
| SOURCES | Source | Metathesaurus FDA Structured Product Labels |
| SOURCES | Source | National Drug Data File Plus Source Vocabulary |
| SOURCES | Source | United States Pharmacopeia |
| SOURCES | Source | US Edition of SNOMED_CT |